Orexigen Therapeutics, Inc.  

(Public, NASDAQ:OREX)   Watch this stock  
Find more results forOREX
+0.11 (3.69%)
Real-time:   2:26pm GMT-4
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.00 - 3.15
52 week 1.65 - 6.49
Open 3.05
Vol / Avg. 178,660.00/280,991.00
Mkt cap 48.52M
P/E     -
Div/yield     -
EPS -3.65
Shares 15.23M
Beta 2.64
Inst. own 48%
Jul 7, 2017
Orexigen Therapeutics Inc Annual Shareholders Meeting (Estimated) - 1:00pm GMT-4 - Add to calendar
May 2, 2017
Q1 2017 Orexigen Therapeutics Inc Earnings Release (Estimated) - 9:30am GMT-4 - Add to calendar
Mar 28, 2017
Q4 2016 Orexigen Therapeutics Inc Earnings Call - Webcast
Mar 28, 2017
Q4 2016 Orexigen Therapeutics Inc Earnings Release
Feb 16, 2017
Orexigen Therapeutics Inc at Leerink Partners Global Healthcare Conference
Feb 14, 2017
Orexigen Therapeutics Inc at Biotechnology Industry Organization (BIO) CEO & Investor Conference
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '16) 2016
Net profit margin -177.26% -72.75%
Operating margin -177.61% -114.76%
EBITD margin - -149.03%
Return on average assets -29.89% -9.07%
Return on average equity -151.32% -54.24%
Employees 132 -
CDP Score - -


3344 N Torrey Pines Ct Ste 200
LA JOLLA, CA 92037-1024
United States - Map
+1-858-8758600 (Phone)
+1-858-8758650 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Orexigen Therapeutics, Inc. is a biopharmaceutical company. The Company is focused on the treatment of obesity. The Company's product, Contrave, is approved in the United States by the United States Food and Drug Administration as an adjunct to a reduced-calorie diet and increased physical activity for chronic weight management in adults with an initial body mass index (BMI) of 30 kilograms per square meter or greater (obese) or 27 kilograms per square meter or greater (overweight) in the presence of a weight-related comorbid condition. Contrave is a combination of generic drug components, each of which has received regulatory approval for other indications and has been commercialized in the United States and in a range of member countries of the European Union. Contrave regulates appetite and energy expenditure through central nervous system (CNS) activity. Contrave is a fixed dose combination of bupropion hydrochloride (HCl) extended release (ER) and naltrexone HCl ER.

Officers and directors

Michael A. Narachi President, Chief Executive Officer, Director
Age: 56
Bio & Compensation  - Reuters
Jason Keyes Chief Financial Officer, Senior Vice President
Bio & Compensation  - Reuters
Thomas R. Cannell Chief Operating Officer, Executive Vice President, President - Global Commercial Products
Age: 54
Bio & Compensation  - Reuters
Thomas P Lynch Executive Vice President, General Counsel, Secretary
Bio & Compensation  - Reuters
Peter Flynn Ph.D. Senior Vice President, Head - Development, Regulatory Affairs and Safety
Bio & Compensation  - Reuters
Toni Foster Senior Vice President - Project Management Office and Clinical Operations
Bio & Compensation  - Reuters
Chris Hazuka Acting General Counsel
Bio & Compensation  - Reuters
Louis C. Bock Independent Director
Age: 50
Bio & Compensation  - Reuters
Brian H. Dovey Independent Director
Age: 75
Bio & Compensation  - Reuters
David J. Endicott Independent Director
Age: 50
Bio & Compensation  - Reuters